Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitolisant in Children and Adolescents With Autism Spectrum Disorders
NCT05953389Phase 2Active, not recruiting
- Sponsor
- Bioprojet
- Start
- Dec 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Pitolisant with Placebo (2 arms). Primary endpoint: Social Responsiveness Scale Second Edition Total Score at 12 weeks. Started Dec 2023; status: active, not recruiting.
02
Drugs
pitolisant
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05953389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05953389.